Biopharmaceutical Firm, Windtree Therapeutics, Inc, primarily based in Warrington, Pennsylvania. introduced that as of August 21, 2025, it is going to droop the contribution of its inventory within the NASDAQ capital markets.
This determination occurred after notification of the US inventory market itself and determined to exempt from repeated violations of contribution customary 5550(a)(2) associated to the bottom value of the inventory.
It is value clarifying The expulsion has nothing to do with the corporate’s enterprise. It is because it reported it – Concentrate on BNB accumulation and stakingcryptocurrency created by Change Binance.
Consequently, the choice of the Nasdaq Windley Frequent Inventoryrecognized by Wint image, They are going to be negotiated in markets outdoors of thrill (For OTC, English acronyms), particularly on the OTCID platform, the corporate had already submitted requests. Nonetheless, we warned that there isn’t a assure that such an utility has been accredited.
After these novelties, Wint’s costs fell by greater than 70% in a couple of minutes, as will be seen within the subsequent TradingView graph.
The corporate emphasised that adjustments to its contribution platform won’t have an effect on its operations or enterprise mannequin. The assertion signed by President and Govt Director Jed Rutkin additionally included a preventive assertion on future forecasts. The corporate emphasised that regardless of the orderly transition to the OTC market, exterior and inner components may have an effect on the end result and acceptance of titles in that market.
The suspension of NASDAQ costs and the relocation to the OTC market marks a brand new chapter in Windree Therapeutics.
